May 3rd, 2019

Devicare is aiming to speed up its growth and will start a 1.5 million Euro crowdfunding round on Capital Cell, the funding platform that specialises in healthcare. With a 1,000 Euro minimum ticket, the company is looking to attract small investors, sponsors, patients and people knowledgeable about innovation and health.

Devicare is a technologically-driven company dedicated to developing digital therapeutic solutions (DTx) to improve in-home management of chronic diseases, combining diagnostics (Dx), monitoring (Mx) and nutritional therapies (Nx). Currently, Devicare has a pioneering solution for the non-surgical treatment of renal lithiasis or kidney stones, called Lit-Control®, with sales agreements in 25 countries with different pharmaceutical companies. With the new resources, the company will continue developing new therapeutic solutions in urology.

Included among the current shareholders is the Investment Holding Company EMESA Corporación Empresarial (owned by Emilio Cuatrecasas) and different Family Offices and corporate partners.

This crowdfunding campaign will lead to a larger round with venture capital funds.

For more information contact Rosendo Garganta, founder and CEO of Devicare (rgarganta@devicare.com).

Follow us on Twitter and LinkedIn with the hashtag #SINLitiasis